首页 > 市场调查报告书 > 製药

基因治疗学和RNAi

市场调查报告书

商品编码

1577049

DNA合成市场、机会、成长动力、产业趋势分析与预测，2024-2032

DNA Synthesis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月07日 | 出版商:

Global Market Insights Inc. | 英文 237 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球DNA 合成市场在2023 年将达到40 亿美元，预计2024 年至2032 年复合年增长率为18.9%。日益采用所推动的。对合成生物学研究的关注得到了大量研发投资和对 DNA 研究的日益重视的支持。此类资金支持技术进步并放大合成生物学在基因组领域的潜力，推动市场成长。

DNA 合成涉及透过在实验室中化学合成核苷酸序列来人工创建 DNA 分子。这些序列用于基因工程、研究和生物技术。

市场依服务分为寡核苷酸合成和基因合成。 2023 年，寡核苷酸合成在分子诊断、基因测试、合成生物学和基因编辑中的作用推动下，以 58% 的份额引领市场。自动合成器和高通量平台等技术进步提高了寡核苷酸合成的可扩展性和效率，进一步推动了市场的发展。

市场也依方法分为基于晶片的合成、基于PCR的酶合成和固相合成。固相合成在2023 年占据了重要的市场份额，预计到2032 年将达到90 亿美元。。此方法的可扩展性和成本效益使其适用于研究和工业应用。

按应用划分，DNA 合成市场包括研发、诊断和治疗。研发领域将在 2023 年引领市场，预计在分析期间复合年增长率为 19.3%。该细分市场的重要市场份额归因于其在推进生物技术和药物研究方面的作用。药物发现、实验研究和基因工程中对客製化 DNA 序列的需求不断增长，推动了 DNA 合成的成长。

该市场按最终用途分为生物製药公司、学术和研究机构以及合约研究组织。生物製药公司领域预计从2024 年到2032 年将以18.4% 的复合年增长率增长。。生物製药公司正在投资 DNA 合成技术，以加快药物发现和开发，从而开发新疗法。

2023年，北美以36.5%的份额引领全球DNA合成市场，预计在分析期间复合年增长率为18.4%。该地区的主导地位得益于强大的研发基础设施以及专注于合成生物学和基因编辑的关键参与者和领先研究机构的集中。这些合作凸显了该地区在推动关键医疗保健解决方案 DNA 合成技术方面的领导地位。

产业生态系统分析
产业影响力
- 成长动力
  - 全球疾病盛行率不断上升
  - 合成生物学领域技术的快速进步
  - 研究与开发（R and D）活动投资不断增加
- 产业陷阱与挑战
  - 严格的政府法规和指导方针
  - 成本高、潜在的生物安全、生物安保和伦理问题
成长潜力分析
监管环境
- 我们
- 欧洲
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
- Thermo fisher scientific Inc.
- Eurofins scientific
- GenScript biotech corporation
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按服务划分，2018 年 - 2032 年

主要趋势
寡核苷酸合成
- 标准寡核苷酸合成
- 客製化寡核苷酸合成
基因合成
- 客製化基因合成
- 基因库合成

第 6 章：市场估计与预测：依方法，2018 - 2032

主要趋势
固相合成
基于PCR的酶合成
基于晶片的合成

第 7 章：市场估计与预测：按应用划分，2018 年 - 2032 年

主要趋势
研究与开发
诊断
疗法

第 8 章：市场估计与预测：依最终用途，2018 年 - 2032 年

主要趋势
生物製药公司
学术及研究机构
合约研究组织

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 10 章：公司简介

BIOMATIK
Bioneer Corporation
Eton Bioscience, Inc.
Eurofins Scientific
GenScript Biotech Corporation
IBA Lifesciences GmbH
Integrated DNA Technologies, Inc.
Kaneka Eurogentec SA
LGC Biosearch Technologies
OriGene Technologies, Inc.
ProMab Biotechnologies, Inc.
ProteoGenix
Quintara Biosciences
Synbio Technologies
Thermo Fisher Scientific Inc.
Twist Bioscience Corporation

简介目录

Product Code: 6000

The Global DNA Synthesis Market garnered USD 4 billion in 2023 and is projected to grow at a CAGR of 18.9% from 2024 to 2032. This growth is driven by advancements in synthetic biology and gene editing technologies, such as CRISPR, and the increasing adoption of precision medicine. The focus on synthetic biology research is supported by substantial R&D investments and an expanding emphasis on DNA studies. Such funding supports technological advancements and amplifies synthetic biology's potential in the genome sector, driving market growth.

DNA synthesis involves the artificial creation of DNA molecules by chemically synthesizing nucleotide sequences in a lab. These sequences are used in genetic engineering, research, and biotechnology.

The market is segmented by service into oligonucleotide synthesis and gene synthesis. In 2023, oligonucleotide synthesis led the market with a 58% share, driven by its role in molecular diagnostics, genetic testing, synthetic biology, and gene editing. Technological advancements, such as automated synthesizers and high-throughput platforms, further boost the market by enhancing the scalability and efficiency of oligonucleotide synthesis.

The market is also segmented by method into chip-based synthesis, PCR-based enzyme synthesis, and solid-phase synthesis. Solid-phase synthesis held a significant market share in 2023 and is projected to reach USD 9 billion by 2032. Its dominance is due to its efficiency and adaptability in constructing DNA sequences on solid supports, allowing for step-by-step nucleotide addition. The method's scalability and cost-effectiveness make it suitable for both research and industrial applications.

By application, the DNA synthesis market includes research and development, diagnostics, and therapeutics. The research and development segment led the market in 2023 and is projected to grow at a CAGR of 19.3% during the analysis period. This segment's significant market share is due to its role in advancing biotechnology and pharmaceutical research. The rising demand for custom DNA sequences in drug discovery, experimental studies, and genetic engineering propels DNA synthesis growth.

The market is segmented by end use into biopharmaceutical companies, academic & research institutes, and contract research organizations. The biopharmaceutical companies segment is projected to grow at a CAGR of 18.4% from 2024 to 2032. This growth is driven by the demand for personalized medicine, where DNA synthesis is crucial in creating treatments tailored to individual genetic profiles. Biopharmaceutical firms are investing in DNA synthesis technologies to expedite drug discovery and development, leading to novel therapies.

In 2023, North America led the global DNA synthesis market with a 36.5% share and is projected to grow at a CAGR of 18.4% during the analysis period. The region's dominance is supported by a strong R&D infrastructure and a concentration of key players and leading research institutions focused on synthetic biology and gene editing. Collaborations highlight the region's leadership in advancing DNA synthesis technologies for critical healthcare solutions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of diseases globally
  - 3.2.1.2 Rapid technology advancements in the field of synthetic biology
  - 3.2.1.3 Rising investments towards research and development (R and D) activities
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent government regulations and guidelines
  - 3.2.2.2 High cost, potential biosafety, biosecurity and ethical issues
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 Thermo fisher scientific Inc.
- 4.1.2 Eurofins scientific
- 4.1.3 GenScript biotech corporation
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Service, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Oligonucleotide synthesis
- 5.2.1 Standard oligonucleotide synthesis
- 5.2.2 Custom oligonucleotide synthesis
5.3 Gene synthesis
- 5.3.1 Custom gene synthesis
- 5.3.2 Gene library synthesis

Chapter 6 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Solid-phase synthesis
6.3 PCR-based enzyme synthesis
6.4 Chip-based synthesis

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Research and development
7.3 Diagnostics
7.4 Therapeutics

Chapter 8 Market Estimates and Forecast, By End use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Biopharmaceutical companies
8.3 Academic and research institutes
8.4 Contract research organizations

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa